Midostaurin
133 interactions 1 explained in plain English 326 cited referencesMidostaurin is used with other chemotherapy drugs to treat certain types of acute myeloid leukemia (AML; a type of cancer of the white blood cells). Midostaurin is also used to certain types of mastocytosis (a blood disorder in which there are too many mast cells [a certain kind of white blood cell]). Midostaurin is in… Read the full Midostaurin drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Midostaurin Tucatinib Tukysa Increased exposure to CYP3A substrate and risk of toxicity Details Midostaurin Ubrogepant Ubrelvy Increased BCRP substrate exposure Details Midostaurin Vonoprazan Voquezna Increased CYP3A substrates exposure Details Midostaurin Vorasidenib Voranigo Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Midostaurin Voriconazole Vfend Increased midostaurin exposure Details Midostaurin Voxelotor Oxbryta Increased exposure of sensitive CYP3A4 substrates Details Midostaurin Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index DetailsModerate
Midostaurin Trospium / Xanomeline Cobenfy Explained Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Midostaurin Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Midostaurin Kratom Increased CYP3A substrate exposure Details Midostaurin Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Midostaurin Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Midostaurin Xanomeline Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist